#1 Clinical Trials Search in Europe

Cx-039776

This article discusses a clinical trial examining the use of mRNA-1010, a candidate seasonal influenza vaccine, in adults aged 50 and older. The study aims to compare the safety, efficacy, and immune response of mRNA-1010 to a licensed inactivated seasonal influenza vaccine. This research is important for developing potentially more effective flu vaccines for older adults, who are often at higher risk of complications from influenza.

Table of Contents

What is CX-039776?

CX-039776 is an investigational mRNA vaccine being developed to prevent influenza (flu) in adults aged 50 and older[1]. It is part of a new vaccine called mRNA-1010, which also includes two other components: CX-044933 and CX-037231. This vaccine is being studied as a potential alternative to currently licensed seasonal flu vaccines.

How Does CX-039776 Work?

As an mRNA vaccine, CX-039776 works differently from traditional flu vaccines. Instead of using weakened or inactivated flu viruses, it uses genetic material (mRNA) to instruct your body’s cells to produce proteins that resemble parts of the flu virus. This helps your immune system recognize and fight against real flu viruses if you’re exposed to them[1].

Clinical Trial Overview

A large-scale clinical trial (Phase 3) is being conducted to evaluate the safety and effectiveness of mRNA-1010, which includes CX-039776. This study compares mRNA-1010 to a licensed seasonal influenza vaccine in adults aged 50 and older[1]. The main goals of this study are:

  • To assess the safety and side effects of mRNA-1010
  • To determine how well mRNA-1010 protects against flu-like illness caused by any influenza A or B strains compared to the licensed vaccine
  • To evaluate the immune response generated by mRNA-1010 compared to the licensed vaccine

Who Can Participate in the Study?

The study is designed for adults aged 50 and older. However, there are specific criteria for who can and cannot participate. Some key points include:

  • Participants must be capable of giving informed consent
  • Women who can become pregnant must use acceptable contraception methods
  • People with certain medical conditions or recent vaccinations may be excluded

It’s important to note that the study excludes individuals who have recently had the flu, received flu vaccines, or been in close contact with someone with confirmed flu[1].

Safety and Effectiveness Measures

The study will closely monitor participants for any side effects or adverse reactions. This includes:

  • Local and systemic reactions: These are immediate responses at the injection site or throughout the body, such as pain, redness, fever, or fatigue.
  • Unsolicited adverse events: Any unexpected health issues that occur after vaccination.
  • Serious adverse events: Any severe health problems that may or may not be related to the vaccine.

To measure effectiveness, the study will track how many participants develop flu-like illness and confirm flu infections using laboratory tests. The researchers will also measure the immune response by looking at antibody levels in participants’ blood[1].

Potential Benefits of CX-039776

While the full benefits of CX-039776 are still being studied, mRNA vaccines like this one have several potential advantages:

  • They can be developed and manufactured more quickly than traditional vaccines, which could be crucial for responding to new flu strains.
  • mRNA vaccines don’t contain live viruses, reducing certain risks associated with some traditional vaccines.
  • They may provide broader protection against multiple flu strains.

However, it’s important to remember that these potential benefits are still being evaluated in the ongoing clinical trial[1].

Aspect Details
Study Type Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven
Participants Adults aged 50 and older
Vaccine Studied mRNA-1010 (experimental) vs. Licensed inactivated seasonal influenza vaccine
Primary Objectives Evaluate safety, reactogenicity, and relative vaccine efficacy against influenza-like illness
Secondary Objectives Assess efficacy against specific flu strains, humoral immunogenicity, and correlates of protection
Key Measurements Adverse reactions, RT-PCR confirmed influenza cases, antibody levels (HAI titers)
Study Duration Approximately 181 days

FAQ

  • What is the main goal of this clinical trial? The main goal is to evaluate the safety and effectiveness of mRNA-1010 compared to a licensed influenza vaccine in adults 50 years and older. The study will look at how well mRNA-1010 protects against flu-like illness caused by any influenza A or B strains.
  • Who can participate in this study? Adults aged 50 and older who meet specific health criteria can participate. Participants must be capable of giving informed consent and follow study requirements. Women who can become pregnant must use acceptable contraception methods.
  • What are some reasons someone might not be able to participate? People who are acutely ill, have recently had the flu or flu vaccine, are participating in other clinical studies, have certain medical conditions, or have had severe reactions to vaccines in the past may not be eligible to participate.
  • How long does the study last? The study lasts approximately 181 days (about 6 months). Participants will be monitored for safety and effectiveness of the vaccine throughout this period.
  • What kind of vaccine is mRNA-1010? mRNA-1010 is an mRNA-based vaccine candidate for seasonal influenza. It uses mRNA technology to stimulate the body's immune response against the flu virus.

Ongoing Clinical Trials on Cx-039776

  • Study of mRNA-1010 Influenza Vaccine Compared to Standard Flu Vaccine in Adults 50 Years and Older

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Estonia Finland Germany

Glossary

  • mRNA vaccine: A type of vaccine that uses genetic material called messenger RNA (mRNA) to teach cells how to make a protein that triggers an immune response against a specific disease.
  • Efficacy: How well a vaccine works in preventing disease under ideal conditions, such as in a clinical trial.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Protocol-defined ILI: Influenza-like illness that meets specific criteria set by the study protocol, used to measure vaccine effectiveness.
  • Hemagglutination Inhibition (HAI): A laboratory test used to measure antibodies against influenza viruses, which helps determine the immune response to flu vaccines.
  • Adverse Event (AE): Any unfavorable or unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it is related to the treatment being studied.
  • Seroconversion: The development of detectable antibodies in the blood against a specific infectious agent, indicating an immune response to vaccination or infection.
  • RT-PCR: Reverse Transcriptase-Polymerase Chain Reaction, a laboratory technique used to detect and confirm the presence of specific viruses, including influenza.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mrna-1010-influenza-vaccine-compared-to-a-licensed-vaccine-for-adults-aged-50-and-older/